Improving delivery of targeted cancer treatments to the brain
Targeting delivery of mAbs to CNS metastases
This study is testing a new way to help deliver cancer-fighting antibodies directly to the brain for patients whose cancer has spread there, using tiny capsules that can better reach the tumor cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10833077 on NIH RePORTER |
What this research studies
This research focuses on enhancing the delivery of monoclonal antibodies (mAbs) to the central nervous system (CNS) for patients with cancers that have spread to the brain. The approach utilizes a novel nano-encapsulation technology that allows these potent therapeutics to cross the blood-brain barrier effectively. By encapsulating mAbs within nanocapsules that are designed to target tumor cells, the treatment aims to improve therapeutic outcomes for patients with brain metastases. The research builds on previous successes in delivering mAbs to the CNS and seeks to optimize this method further.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers that have metastasized to the brain, particularly those who have not responded well to existing treatments.
Not a fit: Patients with cancers that do not spread to the brain or those who are not eligible for monoclonal antibody therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with brain metastases, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown success in using similar nano-encapsulation techniques for delivering therapeutics to the CNS, indicating a promising avenue for further exploration.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Wen, Jing — University of California Los Angeles
- Study coordinator: Wen, Jing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.